Drug Profile


Alternative Names: Hydrochlorothiazide/aliskiren; Rasilez HCT; Riprazo HCT®; Sprimeo HCT®; Tekturna HCT

Latest Information Update: 21 Jul 2016

Price : $50

At a glance

  • Originator Novartis
  • Class Antihypertensives; Benzothiadiazines; Fumarates; Small molecules
  • Mechanism of Action Diuretics; Renin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 06 Jul 2016 Noden Pharma completes acquisition of aliskiren/hydrochlorothiazide from Novartis
  • 24 May 2016 Noden Pharma acquires aliskiren/hydrochlorothiazide from Novartis
  • 19 Apr 2012 Label updates completed following US FDA review of preliminary results from phase III ALTITUDE study in aliskiren
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top